Biological
NKX019
NKX019 is a biological therapy with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting2
Suspended1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
suspended125%
active_not_recruiting125%
recruiting250%
Recent Activity
3 active trials
Showing 4 of 4
suspendedphase_1
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
NCT06518668
active_not_recruitingphase_1
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
NCT05020678
recruitingphase_1
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935
recruitingphase_1
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265
Clinical Trials (4)
Showing 4 of 4 trials
NCT06518668Phase 1
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
NCT05020678Phase 1
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
NCT06733935Phase 1
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06557265Phase 1
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4